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Background/Aims: To compare the effect of levofloxacin and moxifloxacin on treatment outcomes among patients with 
multidrug-resistant tuberculosis (MDR-TB). 
Methods: A retrospective analysis of 171 patients with MDR-TB receiving either levofloxacin or moxifloxacin was 
performed. Treatment responses were categorized into treatment success (cured and treatment completed) or adverse 
treatment outcome (death, failure, and relapsed).
Results: The median age of the patients was 42.0 years. Approximately 56% of the patients were male. Seventeen 
patients had extensively drug-resistant tuberculosis, and 20 had a surgical resection. A total of 123 patients (71.9%) 
received levofloxacin for a median 594 days, and 48 patients (28.1%) received moxifloxacin for a median 673 days. Other 
baseline demographic, clinical, and radiographic characteristics were similar between the two groups. The moxifloxacin 
group had a significantly higher number of resistant drugs (p < 0.001) and a higher incidence of resistance to ofloxacin 
(p = 0.005) in the drug sensitivity test. The treatment success rate was 78.9% in the levofloxacin group and 83.3% in 
the moxifloxacin group (p = 0.42). Adverse reactions occurred at similar rates in the groups (p = 0.44). Patients in the 
moxifloxacin group were not more likely to have treatment success than those in the levofloxacin group (adjusted odds 
ratio, 0.76; 95% confidence interval, 0.24 to 2.43; p = 0.65).
Conclusions: Both levofloxacin and moxifloxacin showed equivalent efficacy for treating MDR-TB. (Korean J Intern Med 
2011;26:153-159)
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INTRODUCTION
Multidrug-resistant tuberculosis (MDR-TB), defined as 
in vitro resistance to at least isoniazid and rifampicins, is 
a growing health concern. An estimated 440,000 (95% 
confidence interval [CI], 390,000 to 510,000) cases of 
MDR-TB, which is 3.6% of all incident TB cases, emerge 
each year, causing 150,000 deaths worldwide [1].
Only a few effective second-line anti-TB drugs are 
available, and those at the forefront are fluoroquinolones 
(FQNs). FQNs show an encouraging in vitro pharmacokinetic 
profile for treating TB [2-5], and current guidelines for 
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managing MDR-TB recommend that all patients be 
treated with FQNs if the strain is susceptible or if the agent 
is thought to have efficacy [5]. In particular, the minimum 
inhibitory concentrations of moxifloxacin are lower than 
those of levofloxacin [3,6], and moxifloxacin exhibits in 
vitro activity [6], and early bactericidal activity [7] that is 
comparable to that of isoniazid. Although several studies 
[8-11] have compared levofloxacin with other FQNs, 
such as ciprofloxacin or ofloxacin, studies comparing 
levofloxacin and moxifloxacin are lacking. This led us to 
conduct a retrospective case-control study of patients 
with MDR-TB who were treated with either levofloxacin or 
moxifloxacin and to compare their treatment outcomes. 
METHODS
Study population   
Patients with MDR-TB receiving either levofloxacin 
or moxifloxacin along with other second-line anti-TB 
medication from January 2002 through December 2008 
were included. Patients were treated in one of three 
hospitals affiliated with Seoul National University College 
of Medicine in Korea: Seoul National University Hospital, 
Seoul Metropolitan Government Seoul National University 
Boramae Medical Center, or Seoul National University 
Bundang Hospital. Mycobacterium tuberculosis was 
identified by sputum culture, and all patients showed 
resistance to at least isoniazid and rifampicins in in vitro 
drug-susceptibility testing. Patients < 18 years of age, 
those treated with both levofloxacin and moxifloxacin 
for TB, and patients who received less than 3 months of 
levofloxacin or moxifloxacin were excluded from analysis. 
This study was approved by the ethics review committees 
of all three hospitals. Previous studies by our group were 
also based on part of this population of patients with 
MDR-TB [12-15].
The choice of FQNs was based on the preference 
of the attending physician, according to the drug-
susceptibility test results. The other combined drugs 
included aminoglycosides, prothionamide, cycloserine, 
pyrazinamide, rifabutin, ethambutol, p-aminosalicylic 
acid, amoxicillin-clavulanic acid, clarithromycin, 
sulfamethoxazole, and trimethoprim. Drugs used before 
the diagnosis of MDR-TB were not included in the analysis. 
Records were reviewed for age, gender, body mass index 
(BMI), underlying comorbidities, smoking history, family 
history of TB, primary drug resistance, laboratory test 
results, radiographic findings, FQN dose, the combination 
of extrapulmonary TB, nontuberculous mycobacteria 
(NTM) colonization, other anti-TB medications, duration 
of treatment, results of drug-susceptibility testing, and 
adverse events.
Definitions of terms and outcomes
Treatment outcomes were classified into the following 
groups in accordance with the suggested criteria of 
Laserson et al. [16]: cure, treatment completed, failure, 
death, default, and transferred out. Additionally, if 
patients were diagnosed with bacteriologically confirmed 
MDR-TB after being cured or after treatment was 
completed, they were considered relapse cases. Based on 
these classifications, treatment outcomes were further 
categorized into treatment success (cured and treatment 
completed) or adverse treatment outcome (death, failure, 
and relapse) to identify predictors of poor treatment 
response.
Extensively drug-resistant tuberculosis (XDR-TB) was 
defined as laboratory-confirmed resistance to all of the 
following: isoniazid, rifampins, any FQNs, and second-
line injectable agents such as capreomycin, kanamycin, 
and amikacin. Although some patients with a poor 
response to treatment had subsequent resistance testing 
performed, they were classified according to the initial 
drug-susceptibility test results. 
Statistical analysis 
Data are expressed as median values with interquartile 
ranges (IQRs) or means ± standard deviations. The 
demographic characteristics, laboratory results, 
radiographic findings, and treatment outcomes were 
compared between the levofloxacin group and the 
moxifloxacin group using Pearson’s χ
2 test or Fisher’s 
exact test for categorical variables and Student’s t test 
for continuous variables. To understand the impact of 
choice between the levofloxacin and moxifloxacin group 
on treatment outcomes, we compared selected clinical 
variables between treatment success and failure through 
a univariate comparison and subsequent multiple logistic 
regression. All statistical analyses were performed with 
SPSS version 11.0 (SPSS Inc., Chicago, IL, USA).Lee JW, et al. Levofloxacin and moxifloxacin for MDR-TB    155
RESULTS
Patient demographic and clinical characteristics 
Between January 2002 and December 2005, 171 
patients received either levofloxacin or moxifloxacin 
to treat MDR-TB. In total, 123 patients (71.9%) were 
treated with levofloxacin and 48 patients (28.1%) received 
moxifloxacin. One-hundred nine patients were from 
Seoul National University Hospital, 26 were from Seoul 
Metropolitan Government Seoul National University 
Boramae Medical Center, and 36 patients were from Seoul 
National University Bundang Hospital. Except for one 
38-year-old Chinese man, all 170 patients were Korean. 
All subjects had radiographic and bacteriologic 
evidence of pulmonary TB, and 20.5% had combined 
extrapulmonary involvement. The most common 
extrapulmonary TB was tuberculous lymphadenopathy 
found in 17 patients (10.5%). The median age of the 171 
patients was 42 years (IQR, 28 to 52). Ninety-six patients 
(56.1%) were male, and 84 patients (49.4%) had a history 
Table 1. Baseline clinical characteristics of the patients who had multidrug-resistant tuberculosis (MDR-TB) treated 
with levofloxacin or moxifloxacin
Total Levofloxacin Moxifloxacin p value
No. of subjects 171 (100)       123 (71.9)         48 (28.1)
Age, yr, median (range)    42.0 (28-52)        42.0 (28-51)        42.0 (28-53) 0.877
Male    96 (56.1)           69 (56.1)          27 (56.3) 0.986
Body mass index, kg/m
2  20.2 ± 3.3 20.4 ± 3.4 19.6 ± 2.8 0.289
Comorbidities
Diabetes
Chronic liver disease
Malignancy
   76 (44.4)
   22 (12.9)
   9 (5.3)
   8 (4.7)
         57 (46.3)
         17 (13.8)
           7 (5.7)
           8 (6.5)
          19 (39.6)
            5 (10.4)
            2 (4.2)
-
0.424
0.550
1.000
0.107
Current/Ex-smoker     58/128
a (45.3)   42/93
a (45.2)    16/35
a (45.7) 0.955
Family history of TB
 b        21/70
a (30.0)     15/49
a (30.6)      6/21
a (28.6) 0.864
Primary drug resistance
c    84 (49.4)         59 (48.4)          25 (52.1) 0.662
Extensively drug-resistant TB  17 (9.9)          10 (8.1) 7 (14.6) 0.255
Admission for treatment    68 (39.8)         52 (42.3)           16 (33.3) 0.283
Laboratory test results
Hemoglobin, g/dL
Hematocrit, %
13.0 ± 1.9
39.4 ± 5.3
13.1 ± 1.9
39.4 ± 5.2
13.0 ± 2.1
39.5 ± 5.6
0.883
0.941
Protein, g/dL   7.3 ± 0.6   7.3 ± 0.6   7.2 ± 0.7 0.394
Albumin, g/dL  4.5 ± 7.4   4.7 ± 8.7   3.9 ± 0.6 0.559
Cholesterol, mg/dL
Serum creatinine, mg/dL
Aspartate aminotransferase, IU/L
Alanine aminotransferease, IU/L
160.8 ± 36.2
  0.9 ± 0.2
 28.8 ± 32.1
    27.5 ± 71.4
  161.0 ± 35.4
  0.9 ± 0.2
  28.8 ± 34.7
  28.9 ± 82.5
160.1 ± 38.5
  1.0 ± 0.2
  28.7 ± 24.6
  23.6 ± 25.6
0.886
0.025
0.983
0.661
Radiographic findings
Cavity  107 (62.6) 77 (62.6)            30 (62.5) 0.990
Bilateral cavities
Extent confined to one lung
   35 (20.5)
   62 (36.3)
23 (18.7)
44 (35.8)
          12 (25.0)
          18 (37.5)
0.359
0.833
Combined extrapulmonary TB    35 (20.5) 27 (22.0) 8 (16.7) 0.442
Nontuberculous mycobacteria colonization   20 (11.7)          12 (9.8) 8 (16.7) 0.206
Values are presented as the mean ± SD or number (%), unless otherwise indicated. p values were based on a comparison between pa-
tients on levofloxacin and patients on moxifloxacin. 
a No. of available data.
b History of tuberculosis among second-degree relatives. 
c MDR-TB patients without prior treatment with anti-TB drugs were classified as having primary resistance.156    The Korean Journal of Internal Medicine Vol. 26, No. 2, June 2011
of TB treatment. Among the previously treated patients, 
64.3% had been treated once, 28.6% twice, and 7.1% more 
than three times. No significant difference was found 
between patients treated with levofloxacin or moxifloxacin 
in terms of BMI, smoking history, family history of TB, 
primary drug resistance, proportion of XDR-TB, and 
radiographic findings (Table 1). However, serum creatinine 
was higher in the moxifloxacin group (0.9 ± 0.2 vs. 1.0 ± 
0.2; p = 0.025) than in the levofloxacin group. Coinfection 
with the human immunodeficiency virus was rare, 
occurring in only one patient in the levofloxacin group. 
NTMs colonization was found in 20 patients (11.7%), and 
the most common NTM identified was Mycobacterium 
abscessus. 
Treatment and outcomes
The median duration of treatment was 594 days 
(IQR, 481 to 772) in the levofloxacin group and 673 days 
(IQR, 530 to 778) in the moxifloxacin group. The usual 
prescribed daily dose of moxifloxacin was 400 mg, and 
the daily dose of levofloxacin varied from 300 to 1,000 
mg. Sixty-eight patients (39.8%) were hospitalized at the 
initiation of treatment, and 20 patients had at least one 
surgical resection of a diseased lung as an adjunctive 
treatment for TB. 
A median of five drugs (range, 4 to 6) were used in the 
MDR-TB treatment, and this was similar between the two 
groups (p = 0.244). However, the number of susceptible 
drugs used was significantly lower in the moxifloxacin 
group (4 vs. 5; p = 0.048) than in the levofloxacin group. 
Furthermore, according to the drug-susceptibility test 
results, the number of resistant drugs (4 vs. 5; p < 0.001) 
and the number of patients with ofloxacin resistance 
(14.6% vs. 35.4%; p = 0.005) was significantly higher in the 
moxifloxacin group than in the levofloxacin group. The use 
of ethambutol was more common in the levofloxacin group 
than in the moxifloxacin group (43.9% vs. 22.9%; p = 0.011) 
and the use of amoxicillin-clavulanate (24.4% vs. 45.8%; 
p = 0.006) was more common in the moxifloxacin group 
than the levofloxacin group (Table 2). The use of other TB 
drugs and the rates of adverse drug reactions were not 
different between the two groups. Isoniazid was used in 
7.6% and rifamycins were used in 6.4% of the patients 
after being diagnosed with multidrug resistance. Among 
Table 2. Treatment modalities and adverse reactions among patients who had multidrug-resistant tuberculosis 
(MDR-TB) treated with levofloxacin or moxifloxacin
Total MDR-TB Levofloxacin Moxifloxacin p value
No. of subjects          171 (100)          123 (71.9)          48 (28.1)
Duration of treatment, days, median (IQR)        614 (494-776)        594 (481-772)     673 (530-778) 0.814
Surgical resection  20 (11.7)   14 (11.4)  6 (12.5) 0.838
No. of used drugs   5 (4-6)    5 (4-6) 5 (4-6) 0.244
No. of susceptible drugs used   5 (4-5)    5 (4-5) 4 (4-5) 0.048
No. of resistant drugs   4 (3-6)     4 (3-5) 5 (4-7) < 0.001
Resistance to ofloxacin   35 (20.5)    18 (14.6) 17 (35.4) 0.005
Adverse drug reactions  81 (47.4)    56 (45.5) 25 (52.1) 0.440
Eye toxicity   2 (1.2)    2 (1.6) - 1.000
Ototoxicity 17 (9.9) 10 (8.1) 7 (14.6) 0.255
Hepatotoxicity 13 (7.6) 10 (8.1) 3 (6.3) 1.000
Hematologic abnormalities   6 (3.5)   2 (1.6) 4 (8.3) 0.053
Gastrointestinal trouble   50 (29.2)    33 (26.8) 17 (35.4) 0.267
Dermatological abnormalities   6 (3.5)    4 (3.3) 2 (4.2) 0.674
Endocrinological abnormalities   4 (2.3)    4 (3.3) - 0.578
Neurological abnormalities   20 (11.7)   13 (10.6)   7 (14.6) 0.463
Allergic reaction  7 (4.1)    7 (5.7) - 0.193
Musculoskeletal abnormalities 13 (7.6)  12 (9.8) 1 (2.1) 0.114
Values are presented as number (%). p values were based on a comparison between patients on levofloxacin and patients on moxifloxacin.
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171 patients, 137 (80.1%) were considered treatment 
successes and 16 (9.4%) were considered treatment 
failures. Eighteen patients (10.5%) were classified as 
default or transfer-out (Table 3). Treatment success was 
achieved among 97 patients (78.9%) in the levofloxacin 
group and 40 (83.3%) in the moxifloxacin group. Based 
on the variables included in the univariate comparison 
between the treatment success and failure groups, the 
final multiple logistic regression model included serum 
creatinine level, resistance to ofloxacin, and the number of 
susceptible drugs used. The patients in the moxifloxacin 
group were not more likely to have treatment success than 
those in the levofloxacin group (adjusted odds ratio, 0.76; 
95% CI, 0.24 to 2.43; p = 0.65; Table 4). 
DISCUSSION
FQNs are one of the most promising classes of TB 
drugs and have been strongly recommended for treating 
MDR-TB [17-20]. As gatifloxacin was removed from 
most markets due to serious adverse drug reactions, 
levofloxacin and moxifloxacin are the two most frequently 
recommended FQNs for treating patients with MDR-TB 
[5,21]. Although clinical data comparing moxifloxacin 
to levofloxacin are scarce, previous in vitro and animal 
studies have reported favorable results for moxifloxacin 
compared to other FQNs [6,22-25]. However, this 
apparent superiority of moxifloxacin against TB was 
not corroborated in our study. A lack of superiority of 
moxifloxacin in our study may have been due to higher 
resistance to ofloxacin and fewer susceptible drugs used 
in the moxifloxacin group compared to the levofloxacin 
group. However, the superiority of moxifloxacin was not 
uncovered even after adjusting for these variables in a 
multivariate analysis. 
The result can be explained by several factors. Although 
a variety of animals has been tested as animal models for 
pulmonary TB, research on animals has its limitations 
and may not adequately reflect human pulmonary TB [26]. 
Furthermore, most of the animal studies [22-24,27,28] 
comparing FQNs for treating TB involved mice. Together 
with the difference in lung pathology, the bacterial loads 
generally remain high in the lungs of infected mice, which 
Table 3. Treatment outcomes among patients who had multidrug-resistant tuberculosis (MDR-TB) treated with 
levofloxacin or moxifloxacin
Total MDR-TB
(n = 171)
Levofloxacin
(n = 123)
Moxifloxacin
(n = 48)
Treatment success                   137 (80.1)    97 (78.9)  40 (83.3)
Cure                   100 (58.5)    68 (55.3)  32 (66.7)
Completed                     37 (21.6)    29 (23.6)    8 (16.7)
Treatment failure                     16 (9.4) 10 (8.1)    6 (12.5) 
Failure                      11 (6.5)    6 (4.9)    5 (10.4)
Death 5 (2.9)    4 (3.3) 1 (2.1)
Others   8 (10.5)   16 (13.0)  2 (4.2)
Default                     12 (7.0) 10 (8.1)  2 (4.2)
Transfer out 6 (3.5)   6 (4.9)
Values are presented as number (%).
Table 4. Multivariate analysis of treatment success comparing moxifloxacin and levofloxacin
Variables Adjusted odds ratio 95% Confidence interval p value
Use of moxifloxacin (vs. levofloxacin) 0.76 0.24 0.65
Serum creatinine level (per 1 mg/dL) 0.82 0.04 0.90
Resistance to ofloxacin 0.45 0.11 0.25
No. of susceptible drugs used
a 1.17 0.68-2.00 0.57
a Odds ratio for an increase of one susceptible drug used.158    The Korean Journal of Internal Medicine Vol. 26, No. 2, June 2011
is different from that in humans [29]. In fact, the effect 
of high-dose levofloxacin (1,000 mg/day) is comparable 
to moxifloxacin in terms of early bactericidal activity in 
patients with pulmonary TB [30].
The use of at least four susceptible drugs has been 
recommended to cure patients with MDR-TB [5,21]. 
Among the various drugs with antimycobacterial 
activities, injectables and FQNs, as well as ethambutol 
and pyrazinamide, are believed to be the most potent for 
patients with MDR-TB. Moreover, the impact of one of four 
or five drugs used to treat patients with MDR-TB may not 
make much difference in terms of outcome. 
Lack of a difference in treatment outcomes between the 
levofloxacin and moxifloxacin groups may be attributable 
to low statistical power. Although the number of patients 
with MDR-TB was comparable to that of other studies, the 
small number of patients in the moxifloxacin group may 
have resulted in insufficient statistical power to detect 
real differences between the two groups. Prospective 
randomized studies enrolling a sufficient number of 
patients with MDR-TB could elucidate the relative 
efficacies among FQNs. 
Treatment response was similar between patients 
who had MDR-TB treated with either levofloxacin or 
moxifloxacin. Further randomized prospective studies are 
warranted to compare the efficacy of FQNs used in a MDR-
TB regimen.
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